Parkinson's disease

Reviews in Clinical Gerontology

Volumn 16, Issue 1, 2006, Pages 1-21

  Macphee, Graeme J A ^a,b   Stewart, David A ^a  

^a QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; DOMPERIDONE; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE;

BASAL GANGLION; BRADYKINESIA; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; DAYTIME SOMNOLENCE; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; HUMAN; INSOMNIA; LEWY BODY; LIVEDO RETICULARIS; NAUSEA; NEUROCHEMISTRY; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; RIGIDITY; SIDE EFFECT; TREMOR; VOMITING;

EID: 33847352509     PISSN: 09592598     EISSN: 14699036     Source Type: Journal    
DOI: 10.1017/S0959259806002073     Document Type: Review

References (189)

1. Hely MA, Morris J, Reid WGJ et al. Sydney multicenter study of Parkinson's disease: non-motor problems dominate5 at 15 years. Mov Disord 2005; 20: 190-99.
2. Schrag A, Jahanshahi M, Quinn NP. What contributes to quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69: 308-12.
3. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease. Mov Disord 2002; 17: 60-67.
4. Findley LJ, Aujla M, Bain P et al. Direct economic impact of Parkinson's disease: a research study in the United Kingdom. Mov Disord 2003; 18: 1139-45.
5. Mutch WJ, Dingwall-Fordyce I, Downie AW et al. Parkinson's disease in a Scottish city. BMJ 1986; 292: 534-36.
6. Chaudhuri KR, Healy D, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-45.
7. Jarman B, Hurwitz B, Cook A. Effects of community-based nurses specialising in Parkinson's disease on health outcome and costs: a randomised control study. BMJ 2002; 324: 1072-75.
8. MacMahon DG, Thomas S. Practical approach to quality of life in Parkinson's disease: the nurse's role. J Neurol 1998; 245(suppl 1): S19-S22.
9. Iansek R. Interdisciplinary rehabilitation in Parkinson's disease. In: Stern GM ed. Advances in Neurology, Vol 80. Philadelphia: Lippincott Williams and Wilkins, 1999: 555-59.
10. Graybiel AM, Hirsch EC, Agid Y. The nigrostriatal system in Parkinson's disease. Adv Neurol 1990; 53: 17-29.
11. Wichmann T. Physiology of the basal ganglia and pathophysiology of movement disorders of basal ganglia origin. In: Watts RL, Koller WC eds. Movement disorders-neurological principles and practice. New York: McGraw-Hill, 1997: 87-97.
12. Gerfen CR, Engber TM, Mahan LC et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250(4986): 1429-32.
13. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-52.
14. Gibb WRG, Lees AJ. Pathological clues to the cause of Parkinson's disease. In: Marsden CD, Fahn S eds. Movement disorders. Oxford: Butterworth-Heinemann, 1994: 147-66.
15. Lennox GG, Lowe JS. Dementia with Lewy bodies. In: Quinn NP ed. Baillìere's Clinical Neurology: Parkinsonism. London: Baillìere Tindall, 1997: 147-66.
16. Spillantini MG, Crowther RA, Jakes R et al. alpha-Synuclein in filamentous inclusions of Lewy bodies and Lewy neurites from Parkinson's disease and dementia with Lewy bodies. Proc Nat Acad Sci USA, 1998; 95: 6469-73.
17. Lowe JS. Lewy bodies. In: Calne DB ed. Neurodegenerative diseases. Philadelphia: WB Saunders, 1994: 51-69.
18. Harrower TP, Michell AW, Barker RA. Lewy bodies in Parkinson's disease: protectors or perpetrators? Exper Neurol 2005; 195: 1-6.
19. Gibb WRG. Functional neuropathology in Parkinson's disease. Eur Neurol 1997; 38(suppl 2): 21-25.
20. Fearnley JM, Lees AJ. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-301.
21. Sagar HJ. Clinicopathological heterogeniety and non-dopaminergic influences on behavior in Parkinson's disease. In: Stern GM ed. Advances in Neurology, Vol 80. Philadelphia: Lippincott, Williams and Wilkins, 1999: 409-17.
22. Gibb WRG. Neuropathology of the substantia nigra. Eur Neurol 1991; 31(suppl 1): 48-59.
23. Gibb WRG, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991; 54: 388-96.
24. Braak H, Del Tredici K, Rub U et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
25. Braak H, Rub U, Jansen Steur EN et al. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64: 1404-10.
26. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119 (Pt 2): 585-91.
27. McKeith IG, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-24.
28. McKeith I,Mintzer J, Aarsland D et al. Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19-28.
29. Perl DP, Olanow CW, Calne DB. Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol 1998; 44(suppl 1): S19-S31.
30. Veldman BAJ, Wijn AM, Knoers N et al. Genetic and environmental risk factors in Parkinson's disease. Clin Neurol Neurosurg 1998; 100: 15-26.
31. Bonifati V, Fabrizio E, Vanacore N et al. Familial Parkinson's disease: a clinical genetic analysis. Can J Neurol Sci 1995; 22: 272-79.
32. Wood N. Genetic aspects of parkinsonism. In: Quinn NP ed. Baillière's Clinical Neurology: Parkinsonism. London: Baillìere Tindall, 1997: 37-53.
33. Piccini P, Burn DJ, Ceravolo R et al. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999; 45: 577-82.
34. Wirdefeldt K, Gatz M, Schalling M et al. No evidence for heritability of Parkinson disease in Swedish twins. Neurology 2004; 63: 305-11.
35. Golbe LI, Dilorio G, Bonavita V et al. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 1990; 27: 276-82.
36. Polymeropoulis MH, Lavedan C, Leroy E et al. Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 1997; 276(5321): 2045-47.
37. Zimprich A, Biskup S, Leitner P et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601-07.
38. Paisan-Ruiz C, Jain S, Evans EW et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44: 595-600.
39. Gilks WP, Abou-Sleiman PM, Gandhi S et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005; 365(9457): 415-16.
40. Marsden CD, Olanow CW. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Ann Neurol 1998; 44(suppl 1): S189-S196.
41. Schapira AHV. Pathogenesis of Parkinson's disease. In: Quinn NP ed. Baillière's Clinical Neurology:Parkinsonism. London: Baillìere Tindall, 1997: 15-36.
42. Dexter DT, Carter CJ, Wells FR et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989; 52: 381-89.
43. Sanchez-Ramos JR, Överick E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994; 3: 197-204.
44. Schapira AH. Disease modification in Parkinson's disease. Lancet Neurol 2004; 3: 362-68.
45. Hong JS. Inflammation in the pathogenesis of Parkinson's disease: Models, mechanisms and therapeutic interventions. Ann NY Acad Sci 2005; 1053: 151-52.
46. Ahlskog JE. Neuroprotective strategies in the treatment of Parkinson's disease: clinical evidence. In: LeWitt PA, Oertel WH eds. Parkinson's disease. The treatment options. London: Martin Dunitz, 1999: 93-115.
47. Weintraub D, Stern M. Psychiatric complications in Parkinson's disease. Am J Geriat Psychiatry 2005; 13: 844-51.
48. Tolosa E, Wenning GK, Poewe WH. The diagnosis of Parkinson's disease. Lancet Neurology 2006; 5: 75-86.
49. Rajput AH. Movement disorders and aging. In: Watts RL, Koller WC eds. Movement disorders: neurological principles and practice. New York: McGraw Hill, 1997: 673-86.
50. Bennet DA, Beckett LA, Murray AM et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Eng J Med 1996; 334: 71-76.
51. Moghal S, Rajput AH, D'Arcy C et al. Prevalence of movement disorders in elderly community residents. Neuroepidemiology 1994; 13: 175-78.
52. Boyle P, Wilson R, Aggarwal N et al. Parkinsonian signs in subjects with mild cognitive impairment. Neurology 2005; 65: 1901-06.
53. Louis ED, Tang M-X, Mayeux R. Parkinsonian signs in older people in a community-based study. Arch Neurol 2004; 61: 1273-76.
54. Bower JH, Maraganore DM, McDonnell SK et al. Incidence and distribution of parkinsonism in Olmstead County, Minnesota 1976-1990. Neurology 1999; 52: 1214-1220.
55. Toth C, Rajput M, Rajput AH. Anomalies of asymmetry of clinical signs in Parkinsonism. Mov Disord 2004; 19: 151-57.
56. Macphee GJA. Diagnosis and differential diagnosis. In: Playfer JR, Hindle JV eds. Parkinson's disease in the older patient. London: Arnold, 2001: 43-76.
57. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497-99.
58. Jankovic J, Rajput AH, McDermott M et al. The evolution of diagnosis in early Parkinson disease. Arch Neurol 2000; 57: 369-72.
59. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28: 99-103.
60. Schrag A, Ben-Shlomo Y, Quinn NP. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2002; 73: 529-34.
61. Hughes AJ, Daniel SE, Blankson S et al. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-48.
62. Quinn N. Parkinsonism - recognition and differential diagnosis. BMJ 1995; 310: 447-52.
63. Katzenschlager R, Cardozo A, Cobo M et al. Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders. Mov Disord 2003; 18: 1123-31.
64. Williams D, de Silva R, Paviour D et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP - parkinsonism. Brain 2005; 128: 1247-58.
65. Deuschl G, Bain P, Brin M et al. Consensus Statement of the Movement Disorder Society on Tremor. Mov Disord 1998; 13: 2-23.
66. Cohen O, Pullman S, Jurewicz E et al. Rest tremor in patients with essential tremor. Arch Neurol 2003; 60: 405-10.
67. Hughes AJ, Daniel SE, Ben-Shlomo Y et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-70.
68. Hughes AJ, Ben-Shlomo Y, Daniel SE et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42: 1142-46.
69. Piccini P, Whone A. Functional brain imaging in the differential diagnosis of Parkinson's disease. Lancet Neurol 2004; 3: 284-90.
70. Benamer HTS, Patterson J, Grosset DG et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123 I]-FP-CIT SPECT imaging: The [123 I]-FP-CIT Study Group. Mov Disord 2000; 15: 503-10.
71. Marshall V, Grosset DG. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003; 18: 1415-23.
72. Braune S. The role of cardiac metaiodobenzylguanadine uptake in the differential diagnosis of parkinsonian syndromes. Clin Autonomic Res 2001; 11: 351-55.
73. Bhatia KP, Brooks DJ, Burn DJ et al. Updated guidelines for the management of Parkinson's disease. Hosp Med 2001; 62: 456-70.
74. Lewis S, Foltynie T, Blackwell A et al. Heterogeneity of Parkinson's disease in the early clinical stages, using a data-driven approach. J Neurol Neurosurg Psychiatry 2005; 76: 343-48.
75. Diamond SG, Markham CH, Hoehn MM et al. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology 1989; 39(1187): 1190.
76. Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology 1985; 35: 522-26.
77. Goetz CG, Tanner CM, Stebbins GT et al. Risk factors for progression in Parkinson's disease. Neurology 1988; 38: 1841-44.
78. Jankovic J, McDermott M, Carvey PM et al. Variable expression of Parkinson's disease: a baseline analysis of the DATATOP cohort. Neurology 1990; 40: 1529-34.
79. Rajput AH, Pahwa R, Pahwa P et al. Prognostic significance of the onset mode in parkinsonism. Neurology 1993; 43: 829-30.
80. Nataraj A, Rajput AH. Parkinson's disease, stroke and related epidemiology. Mov Disord 2005; 20: 1476-80.
81. Schrag A, Quinn NP, Ben-Shlomo Y. Heterogeneity of Parkinson's disease. J Neurol Neurosurg Psychiatry 2006; 77: 275-76.
82. Tanner CM, Kinori I, Goetz CG et al. Age at onset and clinical outcome in idiopathic Parkinson's disease. Neurology 1985; 35(suppl 1): 276.
83. Roos RAC, Jongen JCF, Van Der Velde EA. Clinical course of patients with idiopathic Parkinson's disease. Mov Disord 1996; 11: 236-42.
84. Friedman A. Old-onset Parkinson's disease compared with young-onset disease: clinical differences and similarities. Acta Neurol Scand 1994; 89: 258-61.
85. Hely MA, Morris JGL, Reid WGJ et al. Age at onset: the major determinant of outcome in Parkinson's disease. Acta Neurol Scand 1995; 92: 455-63.
86. Gibb WR, Lees AJ. A comparison of clinical and pathological features of young-and old-onset Parkinson's disease. Neurology 1988; 38: 1402-06.
87. Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000; 47 (suppl 1): 122-30.
88. Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesia. Ann Neurol 2000; 47 (suppl 1): 167-78.
89. Quinn NP. Drug treatment of Parkinson's disease. BMJ 1995; 310: 575-79.
90. Van Camp G, Flamez A, Cosyns B et al. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003; 61: 859-61.
91. Frucht S, Rogers JD, Greene PE et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908.
92. Ferreira JJ, Pona N, Costa J et al. Somnolence as an adverse drug reaction of antiparkinsonian drugs: a meta-analysis of published randomised controlled trials. Mov Disord 2000; 15 (suppl 3): 128.
93. Pal PK, Calne S, Samii A et al. A review of normal sleep and its disturbances in Parkinson's disease. Parkinsonism Related Disord 1999; 5: 1-18.
94. Rascol O, Brooks DJ, Korczyn AD et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Eng J Med 2000; 342: 1484-91.
95. Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson's disease. JAMA 2000; 284: 1931-81.
96. Rinne UK, and the PKDS009 Collaborative Study Group. A five-year double-blind study with cabergoline versus levodopa in the treatment of early Parkinson's disease. Parkinsonism Rel Disord 1999; 5(suppl): S84.
97. Waters CH, Sethi KD, Hauser RA et al. Zydis selegiline reduces off-time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004; 19: 426-32.
98. Asif M, Siddiqui A, Plosker GL. Rasagiline. Drugs Aging 2005; 22: 83-91.
99. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937-43.
100. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson's disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62: 241-48.
101. Rascol O, Brooks DJ, Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO: Lasting effect in Adjunct Therapy with Rasagiline Given Once Daily Study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365(9463): 947-54.
102. Lees AJ, on behalf of the Parkinson's disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild disease. BMJ 1995; 311: 1602-07.
103. Ben-Shlomo Y, Churchyard A, Head J. Investigation by Parkinson's Disease Research Group of the United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early mild Parkinson's disease: further results of a randomised trial and confidential enquiry. BMJ 1998; 316: 1191-96.
104. Ives NJ, Stowe RL, Marro J et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004; 329(7466): 593.
105. Verhagen Metman L, Del Dotto P, Van Der Munckhof P et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50: 1323-26.
106. Metman LV, Del Dotto P, LePoole K et al. Amantadine for levodopa induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56: 1383-86.
107. Luginger E, Wenning GK, Bosch S et al. Beneficial effects of amantadine on levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 1998; 13 (suppl 2): 158.
108. Nutt JG, Woodward WR, Beckner RM et al. Effect of peripheral catechol-Omethyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994; 44: 913-19.
109. Deane KH, Spieker S, Clarke CE et al. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2004; CD004554.
110. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997; 42: 747-55.
111. Brooks DJ, Forsyth D, Playfer JR et al. The role of entacapone in the management of Parkinson's disease. Hosp Med 2000; 61: 267-71.
112. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Eng J Med 1993; 328: 176-83.
113. Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54: 93-101.
114. Parkinson Study Group. Dopamine transporter brain-imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression JAMA 2002; 287: 1653-61.
115. Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson's disease. N Eng J Med 2004; 351: 2498-508.
116. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006; 59: 559-62.
117. Koller W, Lees A, Doder M et al. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord 2001; 16: 858-66.
118. Lundqvist C, Nystedt T, Reiertsen O et al. [Continuous treatment with levodopa of Parkinson disease.] Tidsskrift for Den Norske Laegeforening 2005; 125: 2638-40.
119. Frankel JP, Lees AJ, Kempster PA et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 96-101.
120. MacMahon DG. Use of apomorphine in clinical practice. In: Stern GM ed. Advances in Neurology Vol 80. Philadelphia: Lippincott Williams and Wilkins, 1999: 529-33.
121. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa-induced interdose dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 573-76.
122. Wenning GK, Bosch S, Luginger E et al. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. In: Stern GM ed. Advances in Neurology. Philadelphia: Lippincott Williams and Wilkins, 1999: 545-48.
123. Obeso JA, Guridi J, DeLong M. Surgery for Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 2-8.
124. Lang AE, Lozano AE, Montgomery EB et al. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Eng J Med 1997; 337: 1036-42.
125. Martinez-Martin P, Valldeoriola F, Molinuevo JL et al. Pallidotomy and quality of life in patients with Parkinson's disease: an early study. Mov Disord 2000; 15: 65-70.
126. Krack P, Hamel W, Mehdorn HM et al. Surgical treatment of Parkinson's disease. Curr Opin Neurol 1999; 12: 417-25.
127. Freund H. Long-term effects of deep brain stimulation in Parkinson's disease. Brain 2005; 128: 2222-23.
128. Benabid AL, Chabardes S, Seigneurat E. Deep brain stimulation in Parkinson's disease: long-term efficacy and safety: what happened this year? Curr Opin Neurol 2005; 18: 623-30.
129. Fraix V, Houeto JL, Lagrangre C et al. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006; 77: 443-49.
130. Rodriguez-Oroz M, Obeso JA, Lang AE et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years' follow-up. Brain 2005; 128: 2240-49.
131. Uitti RJ, Wharen RE, Turk MF et al. Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patients. Neurology 1997; 49: 1072-1077.
132. Burn DJ, Troster A. Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease. J Geriat Psychiatry Neurol 2004; 17: 172-80.
133. Lang AE, Lozano AE. Parkinson's disease: second of two parts. N Eng J Med 1998; 339: 1130-43.
134. Freed C, Greene PE, Breeze R et al. Transplantation of embryonic dopamine neurones for severe Parkinson's disease. N Eng J Med 2001; 344: 710-19.
135. Olanow CW, Goetz CG, Kordower J et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-14.
136. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004; 3: 309-16.
137. Goetz CG, Stebbins GT. Risk factors for nursing-home placement in advanced Parkinson's disease. Neurology 1993; 43: 2227-29.
138. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 2006; 113: 211-20.
139. Poewe WH, Wenning GK. The natural history of Parkinson's disease. Ann Neurol 1998; 44(suppl 1): S1-S9.
140. Postuma R, Lang AE, Massicote-Marquez J et al. Potential early markers of Parkinson's disease in idiopathic REM sleep behaviour disorder. Neurology 2006; 66: 845-51.
141. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003; 18: 738-50.
142. Ramaker C, Marinus J, Stiggelbout A et al. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord 2002; 17: 867-76.
143. Chaudhuri KR, Martinez-Martin P, Schapira AHV et al. An international multicentre pilot study of the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson's disease: the NMS Quest Study. Mov Disord (in press) 2006.
144. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229-37.
145. Aarsland D, Tandberg E, Larsen JP et al. Frequency of dementia in Parkinson's disease. Arch Neurol 1996; 53: 538-42.
146. Aarsland D, Andersen K, Larsen J-P et al. Prevalence and characteristics of dementia in Parkinson's disease: an eight-year prospective study. Arch Neurol 2003; 60: 387-92.
147. Foltynie T, Brayne C, Robbins T et al. The cognitive ability of an incident cohort of Parkinson's patients in the UK. Brain 2004; 127: 550-60.
148. Brown RG, Marsden CD. Neuropsychology and cognitive function in Parkinson's disease: an overview. In: Fahn S, Marsden CD, eds. Movement Disorders 2. London: Butterworth, 1987: 99-123.
149. Cummings JL. Frontal subcortical circuits and human behaviour. Arch Neurol 1993; 50: 873-880.
150. Ebmeier KP, Calder SA, Crawford JR et al. Clinical features predicting dementia in idiopathic Parkinson's disease. Neurology 1990; 40: 1222-24.
151. Stern Y, Marder K, Tang M-X et al. Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 1993; 43: 1690-92.
152. Biggins CA, Boyd JL, Harrop FM et al. A controlled longitudinal study of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 566-71.
153. Hurtig HI, Trojanowski JQ, Galvin J et al. Alpha synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54: 1916-21.
154. Colosimo C, Hughes AJ, Killard L et al. Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74: 852-56.
155. Jellinger KA. The neuropathologic diagnosis of secondary parkinsonian syndromes. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S eds. Advances in Neurology Philadelphia: Lippincott-Raven, 1996: 293-303.
156. Perry E, Kilford L, Lees AJ et al. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003; 54: 235-38.
157. Emre M, Aarsland D, Albanese A et al. Rivastigmine for the treatment of dementia associated with Parkinson's disease. N Eng J Med 2004; 351: 2509-18.
158. McKeith I, Del Ser T, Spano P et al. Effect of rivastigmine in dementia with Lewy bodies: a randomised double-blind placebo-controlled international study. Lancet 2000; 356: 2031-36.
159. McKeith I, Dickson D, Lowe J et al. Diagnosis and management of dementia with Lewy bodies. Third Report of the DLB consortium. Neurology 2005; 65: 1863-72.
160. Aarsland D, Laake K, Larsen J-P et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708-12.
161. Chaudhuri KR. Nocturnal symptom complex in PD and its management. Neurology 2003; 61(suppl 3): S17-S23.
162. Arnulf I, Konofal E, Merino-Andreu M et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58: 1019-24.
163. Adler C, Caviness J, Hentz J et al. Randomised trial of modafanil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003; 18: 287-93.
164. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 4: 443-54.
165. Allain H, Schuck S, Mauduit N. Depression in Parkinson's disease. BMJ 2000; 320: 1287-88.
166. Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. Age Ageing 1999; 28: 35-38.
167. Marsh L, McDonald W, Cummings JL et al. Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group. Mov Disord 2006; 21: 148-58.
168. Brown R, Jahanshahi M. Depression in Parkinson's disease: a psychosocial viewpoint. In: Weiner W, Lang AE eds. Advances in Neurology, Vol 65. New York: Raven Press, 1995: 61-84.
169. Starkstein SE, Mayberg HS, Leiguarda R et al. A prospective longitudinal study of depression, cognitive decline and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 377-82.
170. Kuzis G, Sabe L, Tiberti C et al. Cognitive functions in major depression and Parkinson's disease. Arch Neurol 1997; 54: 982-86.
171. Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002; 17: 445-54.
172. Rektorova I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease. Eur J Neurol 2003; 10: 399-406.
173. Miyasaki JM, Shannon KM, Voon V et al. Practice parameter: evaluation and treatment of depression, psychosis and dementia in Parkinson's disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996-1002.
174. Lieberman A. Depression in Parkinson's disease. Acta Neurol Scand 2006; 113: 1-8.
175. Richard IH, Kurlan R, Factor SA. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 1997; 48: 1070-77.
176. Wolters EC. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis. Neurology 1999; 52(suppl 3): S10-S13.
177. Goetz CG, Wenging F, Leurgans S et al. The malignant course of 'benign hallucinations' in Parkinson's disease. Arch Neurol 2006; 63: 235-238.
178. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982; 139: 494-97.
179. Goetz CG, Stebbins GT. Mortality and hallucination in nursing-home patients with advanced Parkinson's disease. Neurology 1995; 45: 669-71.
180. Goetz CG, Vogel C, Tanner CM et al. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998; 51: 811-14.
181. Williams D, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005; 4: 605-10.
182. Liang T-S, Duda J, Trojanowski JQ et al. Visual hallucinations and alpha synuclein pathology in parkinson's disease and dementia with Lewy bodies. Neurology 2005; 64: 82-89.
183. Tanner CM, Vogel C, Goetz CG et al. Hallucinations in Parkinson's disease: a population study. Ann Neurol 1983; 14: 136.
184. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson's disease. Arch Neurol 1996; 53: 1265-68.
185. Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63: 434-40.
186. Merims D, Shabtai H, Korczyn AD et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm 2004; 111: 1447-53.
187. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15: 201-11.
188. Evans A, Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 2004; 17: 393-98.
189. Chaudhuri KR. Autonomic dysfunction in Parkinson's disease. Curr Opin Neurol 2001; 14: 505-11.